Organization
Paris and Saint Cloud
6 abstracts
Abstract
Dynamics and type of ESR1 mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial.Org: Gustave Roussy Cancer Center, CARIO - HPCA, Department of Genetics, Claudius Regaud Institute, Eugène Marquis Comprehensive Cancer Center,
Abstract
Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D.Org: Saint-Louis Hospital, APHP, University Paris Cité, Paris and Saint Cloud, France,
Abstract
ECLECTIC: 18F-fluoroestradiol PET and circulating biomarkers to guide the choice of the second line therapy for ER+, HER2- metastatic breast cancer: A phase 3 trial.Org: Institut Curie, Saint Cloud, France, Paris and Saint Cloud, France, Centre Oscar Lambret, Lille University Hospital,
Abstract
Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study.Org: Institut de Cancerologie de l'Ouest, ICO Institut de Cancerologie de l'Ouest, Institut de Cancérologie de l'Ouest, Centre Antoine Lacassagne, Centre Georges Francois Leclerc,
Abstract
The impact of self-reported social determinants of health (SDOH) on patient engagement and symptom burden across a remote patient monitoring (RPM) pathway in 42 European hospitals.Org: Cancer Survivorship Program, INSERM 981, Gustave Roussy, Villejuif, France, INSERM Unit 981, Gustave Roussy Cancer Center, Villejuif, France, Patient Pathway Division,
Abstract
TOPOLOGY: A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer.Org: Institut Curie, Saint Cloud, France, Hopital Privé des Cotes d'Armor, Paris and Saint-Cloud, Medical Oncology Department and D3i, Paris and Saint Cloud,